BMS Terminates PRX019 License; Prothena Loses Up to $617.5M in Milestones
PRTA is trading near its 52-week low of $7.73 (15% above the low).
Summary
Bristol Myers Squibb is dropping PRX019 and terminating the license effective January 28, 2027, so Prothena gets none of the up to $617.5 million in remaining milestones or royalties. The Phase 1 data had been clean, making this a partner strategy call rather than a safety problem.
Key Events · M&A and Partnerships · PRTA
-
BMS Terminates PRX019 License
Bristol Myers Squibb informed Prothena on October 28, 2026 that it will not advance PRX019 further in the clinic; the May 2024 exclusive global license agreement terminates January 28, 2027.
-
Up to $617.5M in Milestones Forfeited
Prothena keeps the $80 million upfront already received but will get none of the up to $617.5 million in development, regulatory and sales milestones, and no tiered royalties, on PRX019.
-
Clean Phase 1 Data Did Not Save Program
The first-half 2026 Phase 1 trial showed benign safety and tolerability, no immunogenicity, and dose-dependent PK/PD hitting prespecified targets — the termination reflects BMS portfolio strategy, not a safety signal.
-
Moponetug Remains the Live BMS Asset
BMS continues the Phase 2 TargetTau-1 trial of moponetug (formerly PRX005) in early Alzheimer's; Prothena has received $135 million in licensing payments and is eligible for up to $562.5 million in regulatory and sales milestones plus tiered royalties.
Analysis · PRTA · Life Sciences
Bristol Myers Squibb told Prothena on October 28 that it will not advance PRX019 into further clinical testing, and the May 2024 global license agreement terminates January 28, 2027. Prothena collected an $80 million upfront in 2024 but now forfeits the entire remaining package of up to $617.5 million in development, regulatory and sales milestones plus tiered royalties — a large chunk of the partnered-pipeline value the market had been carrying. The Phase 1 data were clean (benign safety, no immunogenicity, dose-dependent PK/PD), so this is a partner portfolio decision rather than a safety failure, but it removes a late-stage optionality leg and leaves the moponetug Alzheimer's program as the main BMS partnership. Against a roughly $456 million market cap, losing a program with $617.5 million of headline milestones is a material hit to the story, partly offset by the company's $100 million buyback authorization and heavy insider buying by 10% owner William Scully over the past three months.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRTA was trading at $8.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $455.9M. The 52-week trading range was $7.73 to $11.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.